| Abstrakt: |
Objective: To observe the expression level of long non-coding RNA FLJ26245 (lncRNA FLJ26245) in prostate cancer tissues and cells, and to explore its effect on the proliferation and migration of prostate cancer PC-3 cells and the underlying mechanism. Methods: A total of 52 pairs of prostate cancer tissues and corresponding para-cancerous tissues from patients who underwent surgery at Luoyang Central Hospital from March 2017 to May 2019 were collected for this study; in addtion, the prostate cancer cell lines (LNCaP, C4-2B, PC-3, DU-145) and normal prostate epithelial cells (RWPE-1) were also selected. qPCR was used to detect the expression level of FLJ26245 in prostate cancer tissues and cells. FLJ26245 mimics and negative control plasmids (lncR-NC) were transfected into PC-3 cells, respectively. MTT assay and Wound-healing test were used to detect the proliferation and migration ability of prostate cancer cells. Bioinformatics technology was used to predict the targeting relationship among FLJ26245, miR-200a-3p, and tyrosine phosphatase receptor G (PTPRG), which was further validated with Dual luciferase reporter gene assay. qPCR and WB methods were used to detect the expression of FLJ26245 downstream gene and proliferation and migration related proteins, respectively. Results: Compared with para-cancerous tissues, the expression level of FLJ26245 in prostate cancer tissues was significantly downregulaed (P<0.01). Compared with RWPE-1 cells, the expression level of FLJ26245 in prostate cancer cells was also significantly decreased (P<0.01 or P<0.05), with the lowest expression in PC-3 cells (P<0.01). Overexpression of FLJ26245 could significantly inhibit the proliferation and migration ability of PC-3 cells (P<0.05 or P<0.01). FLJ26245 could bind to miR-200a-3p, and miR-200a-3p could bind to PTPRG (all P<0.01). After overexpression of FLJ26245, the expression of miR-200a-3p in PC-3 cells was significantly decreased (P<0.01), the mRNA and protein expressions of PTPRG were significantly increased (all P<0.01), and proliferation and migration related proteins, such as cyclin A, CDK2 and Twist, N-cadherin, were significantly reduced (all P<0.01). Conclusion: FLJ26245 is low expressed in prostate cancer tissues and cells. FLJ26245 may inhibit the proliferation and migration of prostate cancer PC-3 cells by regulating the miR-200a-3p/PTPRG axis. [ABSTRACT FROM AUTHOR] |
